Novo Nordisk Reports Positive Phase 3 CagriSema Resultsx
Bagsværd, Denmark, September 21, 2026 Novo Nordisk has announced topline results from two Phase 3 trials evaluating CagriSema, an...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Bagsværd, Denmark, September 21, 2026 Novo Nordisk has announced topline results from two Phase 3 trials evaluating CagriSema, an...
Caesarea, Israel, September 15, 2026 Nitinotes has announced the completion of the first EASE™ clinical trial procedures at Fondazione...
SAN FRANCISCO — September 8, 2026 Structure Therapeutics reported positive clinical data across its two lead oral small-molecule programs...
Hong Kong, September 8, 2026 Ascletis Pharma Inc. has announced the initiation of a U.S. Phase 1 clinical trial...
Beijing, China & Florence, Italy, September 3, 2026 Gan & Lee Pharmaceuticals and The Menarini Group have entered into...
Zepbound Use Associated With Lower Healthcare Costs INDIANAPOLIS, Aug. 26, 2026 — Eli Lilly and Company announced new real-world...
SEOUL, South Korea, August 24, 2026 Hanmi Pharm announced an exclusive global licensing agreement with Genentech, a member of...
Hong Kong, China, August 10, 2026 Ascletis Pharma Inc. has announced the initiation of two Phase I clinical studies...
ALAMEDA, Calif., August 6, 2026 Vivani Medical, Inc. announced the successful full enrollment and initial dosing of all 20...
Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...
